Health state utility scores in advanced non-small cell lung cancer

Lung Cancer

Volumn 62, Issue 3, 2008, Pages 374-380

  Doyle, Scott ^a   Lloyd, Andrew ^b   Walker, Mel ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ICON PLC   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Carcinoma; Costs and cost analysis; Economics; Lung neoplasms; Non small cell lung; Patient satisfaction; Quality of life

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CONTENT VALIDITY; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DYSPNEA; FACE VALIDITY; FEMALE; HEALTH STATUS; HUMAN; INTERVIEW; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; PAIN; PRIORITY JOURNAL; PSYCHOMETRY; SYMPTOM; TREATMENT RESPONSE; UNITED KINGDOM; VISUAL ANALOG SCALE;

ADULT; ATTITUDE TO HEALTH; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG TOXICITY; FEMALE; HEALTH STATUS; HUMANS; INTERVIEWS AS TOPIC; LUNG NEOPLASMS; MALE; PILOT PROJECTS; PSYCHOMETRICS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 56949106092     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.019     Document Type: Article

References (21)

1. Cooley M., Short T., and Moriarty H. Symptom prevalence, distress, and change over time in adults receiving treatment for lung cancer. Psycho-Oncology 12 (2003) 694-708
2. Gralla R., and Thatcher N. Quality of life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer 46 S2 (2004) S41-S47
3. Numico G., Russi E., and Merlano M. Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy?. Lung Cancer 32 3 (2001 Jun) 213-226
4. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., and Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A 5 (1994) 635-642
5. Cella D.F., Bonomi A.E., Lloyd S.R., Tulsky D.S., Kaplan E., and Bonomi P. Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 12 3 (1995) 199-220
6. Gold M., Siegel J.E., Russell L.B., and Weinstein MC. Cost effectiveness in health and medicine (1996), Oxford University Press, New York
7. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B. (Ed). Quality of life and pharmacoeconomics in clinical trials. second ed. (1996), Lippincott-Raven Publishers, Philadelphia 191-201
8. Feeny D.H., Torrance G.W., and Furlong W.J. Health Utilities Index, Chapter 26. In: Bert Spilker (Ed). Quality of life and pharmacoeconomics in clinical trials. second ed. (1996), Lippincott-Raven Press, Philadelphia 239-252
9. Lloyd A., van Hanswijck de Jonge P., Doyle S., Walker M., and Farina C. Development and elicitation of health state utilities in metastatic non-small cell lung cancer (NSCLC) in the UK. Presented at the 27th Annual Meeting of the Society for Medical Decision Making (2005)
10. Torrance G.W. Preferences for health states: a review of measurement methods. Clinical and economic evaluation of perinatal and developmental medicine. Mead Johnson Symp Perinat Dev Med 20 (1982) 37-45
11. Torrance G.W. Measurement of health state utilities for economic appraisal. J Health Econ 5 1 (1986) 1-30
12. Torrance G.W. Utility approach to measuring health-related quality of life. J Chronic Dis 40 6 (1987) 593-600
13. Brooks R. EuroQol: the current state of play. Health Policy 37 1 (1996 Jul) 53-72
14. Bennett K., and Torrance G. Measuring health state preferences and utilities: Rating scale, time trade-off and standard gamble techniques. In: Spilker B. (Ed). HRQL and pharmacoeconomics in clinical trials. second ed. (1996), Lippincott-Raven, Philadelphia 253-266
15. Office of National Statistics, National Statistics website "Population of the United Kingdom: by ethnic group, April 2001" http://www.statistics.gov.uk/cci/nugget_print.asp?ID=764.
16. Kind P., Dolan P., Gudex C., and Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316 (1998) 736-741
17. de Leeuw J., and Kreft I.G.G. Random coefficient models for multilevel analysis. J Educat Stat 11 (1986) 57-86
18. Earle C.C., Chapman R.H., Baker C.S., Bell C.M., Stone P.W., Sandberg E.A., and Neumann P.J. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18 18 (2000) 3302-3317
19. Raab S.S., and Hornberger J. The effect of a patient's risk-taking attitude on the cost effectiveness of testing strategies in the evaluation of pulmonary lesions. Chest 111 (1997) 1583-1590
20. Kind P., and Macran S. Eliciting social preference weights for functional assessment of cancer therapy-lung health states. Pharmacoeconomics 23 11 (2005) 1143-1153
21. Winterhlader R.C., Hirsch F.R., Kotantoulas G.K., Franklin W.A., and Bunn P.A. Chemoprevention of lung cancer-from biology to clinical reality. Ann Oncol 15 (2004) 185-196